Strategic License Agreement - Narrative (Details) - USD ($)			1 Months Ended	12 Months Ended
	Jul. 27, 2023	Mar. 21, 2021	Jul. 31, 2021	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Total revenue				$ 0	$ 886,000	$ 2,329,000
Proceeds from sale of in-process research & development asset				0	15,000,000	0
Gain on sale of in-process research and development asset				0	16,449,000	0
Contract assets				0	0
Contract liability				$ 0	0
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Global Rights To Pegzilarginase
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Proceeds from sale of in-process research & development asset	$ 15,000,000.0
Contingent consideration	100,000,000.0
Carrying value of assets	0
Gain on sale of in-process research and development asset	16,400,000
Contingent reimbursement of pre-paid manufacturing costs	1,800,000
Derecognition of nonfinancial assets and liabilities	$ 400,000
Immedica Pharma AB
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Reimbursement			$ 3,000,000.0
Rate of revenue share		25.00%
Immedica Pharma AB | PEACE Trial and BLA Package
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Total revenue					$ 900,000	$ 2,300,000